Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA's NDA And BLA Approvals: Fiasp, Ascor

Executive Summary

Original new drugs and biologics approved by US FDA.

You may also be interested in...

Lilly’s Ultra Rapid Lispro Mealtime Insulin Sails Through Phase III, But Will It Be Enough?

With only slight potential advantages in some types of patients, ultra-rapid insulins will likely still need to compete on price to be more widely successful, analysts say.

Novo Nordisk’s Ultra Fast-Acting Insulin On Course To Indian Debut

Novo Nordisk is gearing towards the potential launch of its ultra fast-acting insulin aspart, Fiasp, in India. Pricing and how the product will be positioned alongside NovoRapid (conventional insulin aspart) are expected to be closely watched by competition.

J&J And Sanofi Team Up On Phase III E. Coli Vaccine

Sanofi will pay $175m up front for rights to commercialize J&J’s potential first-in-class vaccine against E. coli. The two companies will share profits.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts